Crinetics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2008-01-01

Employees: 290

Market Cap: $4.3B

Website: http://www.crinetics.com

Introduction: Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Clinical Trials

An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894

Phase 2

Recruiting

Conditions: Congenital Adrenal Hyperplasia
Classic Congenital Adrenal Hyperplasia

Interventions: Drug: atumelnant (CRN04894)

First Posted Date: 2024-12-02

Last Posted Date: 2024-12-02

Lead Sponsor: Crinetics Pharmaceuticals Inc.

Target Recruit Count: 150

Registration Number: NCT06712823

Locations: 🇺🇸
Crinetics Study Site, Morehead City, North Carolina, United States

Single and Multiple-Ascending Dose Study of CRN04894 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CRN04894 Oral Solution
Drug: Placebo Oral Solution

First Posted Date: 2023-09-21

Last Posted Date: 2023-09-21

Lead Sponsor: Crinetics Pharmaceuticals Inc.

Target Recruit Count: 88

Registration Number: NCT06048887

Locations: 🇺🇸
QPS-Miami Research Associates, Miami, Florida, United States

Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

Phase 2

Recruiting

Conditions: Classic Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia

Interventions: Drug: CRN04894

First Posted Date: 2023-06-18

Last Posted Date: 2024-11-26

Lead Sponsor: Crinetics Pharmaceuticals Inc.

Target Recruit Count: 30

Registration Number: NCT05907291

Locations: 🇬🇧
Crinetics Study Site, London, United Kingdom

A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

Phase 1

Recruiting

Conditions: Cushing Syndrome
Cushing Disease
Ectopic ACTH Syndrome

Interventions: Drug: CRN04894

First Posted Date: 2023-04-07

Last Posted Date: 2024-07-26

Lead Sponsor: Crinetics Pharmaceuticals Inc.

Target Recruit Count: 18

Registration Number: NCT05804669

Locations: 🇺🇸
National Institutes of Health (NIH) - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, United States

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Phase 2

Active, not recruiting

Conditions: Carcinoid Syndrome
Carcinoid Tumor of Ileum
Carcinoid Intestine Tumor
Carcinoid Tumor of Liver
Carcinoid Tumor
Carcinoid Tumor of Cecum
Carcinoid Syndrome Diarrhea
Carcinoid Tumor of Pancreas
Carcinoid

First Posted Date: 2022-05-05

Last Posted Date: 2024-02-01

Lead Sponsor: Crinetics Pharmaceuticals Inc.

Target Recruit Count: 36

Registration Number: NCT05361668

Locations: 🇵🇪
Crinetics Study Site Peru #2, Lima, Peru
🇵🇱
Crinetics Study Site, Wrocław, Poland
🇵🇪
Crinetics Study Site Peru #1, Lima, Peru

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)

Phase 3

Active, not recruiting

Conditions: Acromegaly

Interventions: Drug: Placebo
Drug: Paltusotine

First Posted Date: 2022-01-14

Last Posted Date: 2024-03-29

Lead Sponsor: Crinetics Pharmaceuticals Inc.

Target Recruit Count: 111

Registration Number: NCT05192382

Locations: 🇬🇧
Crinetics Study Site, London, United Kingdom
🇬🇷
Crinetics Study Site (a), Athens, Greece
🇬🇷
Crinetics Study Site (b), Athens, Greece

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly

Phase 3

Active, not recruiting

Conditions: Acromegaly

Interventions: Drug: Placebo
Drug: Paltusotine

First Posted Date: 2021-04-08

Last Posted Date: 2024-07-10

Lead Sponsor: Crinetics Pharmaceuticals Inc.

Target Recruit Count: 58

Registration Number: NCT04837040

Locations: 🇬🇧
Crinetics Study Site, London, United Kingdom

A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)

Phase 2

Active, not recruiting

Conditions: Acromegaly

Interventions: Drug: Paltusotine

First Posted Date: 2020-02-10

Last Posted Date: 2024-12-18

Lead Sponsor: Crinetics Pharmaceuticals Inc.

Target Recruit Count: 43

Registration Number: NCT04261712

Locations: 🇬🇷
Crinetics Study Site 1, Athens, Greece
🇬🇷
Crinetics Study Site 2, Athens, Greece
🇬🇧
Crinetics Study Site, Leeds, United Kingdom

Mass Balance and Pharmacokinetics of [14C]-CRN00808 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: [14C]-CRN00808
Drug: CRN00808

First Posted Date: 2020-01-29

Last Posted Date: 2020-01-29

Lead Sponsor: Crinetics Pharmaceuticals Inc.

Target Recruit Count: 11

Registration Number: NCT04246749

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands

A Single and Multiple-Ascending Dose Study of CRN01941 in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CRN01941 Oral Solution
Drug: CRN01941 Oral Capsule
Drug: Placebo Oral Solution
Drug: Placebo Oral Capsule

First Posted Date: 2019-05-03

Last Posted Date: 2020-11-04

Lead Sponsor: Crinetics Pharmaceuticals Inc.

Target Recruit Count: 57

Registration Number: NCT03936166

Locations: 🇦🇺
Linear Clinical Research, Perth, Western Australia, Australia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy